Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KELLY K HUNT and KHANDAN KEYOMARSI.
KELLY K HUNT
Connection Strength
7.535
KHANDAN KEYOMARSI
  1. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.
    View in: PubMed
    Score: 0.571
  2. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 2013 Jan 15; 15(1):R3.
    View in: PubMed
    Score: 0.437
  3. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol. 2005 Aug; 15(4):319-26.
    View in: PubMed
    Score: 0.261
  4. Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res. 2024 Nov 15; 84(22):3864-3880.
    View in: PubMed
    Score: 0.248
  5. Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. Mol Cancer Ther. 2024 Apr 02; 23(4):492-506.
    View in: PubMed
    Score: 0.238
  6. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics. Cancers (Basel). 2024 Jan 24; 16(3).
    View in: PubMed
    Score: 0.235
  7. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
    View in: PubMed
    Score: 0.230
  8. Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
    View in: PubMed
    Score: 0.221
  9. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene. 2022 Dec; 41(50):5331-5346.
    View in: PubMed
    Score: 0.216
  10. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022 06 15; 150(12):2025-2037.
    View in: PubMed
    Score: 0.206
  11. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.
    View in: PubMed
    Score: 0.198
  12. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40.
    View in: PubMed
    Score: 0.195
  13. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7).
    View in: PubMed
    Score: 0.193
  14. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. Br J Cancer. 2020 03; 122(6):812-822.
    View in: PubMed
    Score: 0.178
  15. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019 07 01; 25(13):3996-4013.
    View in: PubMed
    Score: 0.168
  16. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res. 2018 10 01; 78(19):5481-5491.
    View in: PubMed
    Score: 0.162
  17. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
    View in: PubMed
    Score: 0.162
  18. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018 02 01; 78(3):742-757.
    View in: PubMed
    Score: 0.153
  19. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7288-7300.
    View in: PubMed
    Score: 0.151
  20. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 06 27; 8:15916.
    View in: PubMed
    Score: 0.149
  21. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther. 2017 09; 16(9):1751-1764.
    View in: PubMed
    Score: 0.148
  22. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017 Feb 28; 8(9):14897-14911.
    View in: PubMed
    Score: 0.145
  23. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res. 2017 01; 15(1):45-58.
    View in: PubMed
    Score: 0.141
  24. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol. 2016 07; 186(7):1900-1912.
    View in: PubMed
    Score: 0.138
  25. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 2016 06 17; 15(12):1579-90.
    View in: PubMed
    Score: 0.137
  26. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res. 2016 04 15; 76(8):2406-18.
    View in: PubMed
    Score: 0.136
  27. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther. 2016 04; 15(4):593-607.
    View in: PubMed
    Score: 0.135
  28. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. 2016 05 12; 35(19):2428-40.
    View in: PubMed
    Score: 0.131
  29. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87.
    View in: PubMed
    Score: 0.129
  30. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67.
    View in: PubMed
    Score: 0.123
  31. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417.
    View in: PubMed
    Score: 0.117
  32. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res. 2013 Sep 01; 73(17):5556-68.
    View in: PubMed
    Score: 0.114
  33. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 2013 Oct; 34(10):2244-52.
    View in: PubMed
    Score: 0.112
  34. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538.
    View in: PubMed
    Score: 0.103
  35. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther. 2011 Jul; 18(7):510-9.
    View in: PubMed
    Score: 0.097
  36. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res. 2010 Sep 15; 70(18):7125-36.
    View in: PubMed
    Score: 0.093
  37. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010 Jun 15; 70(12):5074-84.
    View in: PubMed
    Score: 0.091
  38. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907.
    View in: PubMed
    Score: 0.091
  39. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle. 2010 Mar 15; 9(6):1122-30.
    View in: PubMed
    Score: 0.090
  40. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010 Feb 15; 16(4):1179-90.
    View in: PubMed
    Score: 0.089
  41. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009 Apr 01; 8(7):1062-8.
    View in: PubMed
    Score: 0.084
  42. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res. 2009 Apr 01; 69(7):2817-25.
    View in: PubMed
    Score: 0.084
  43. Biomarkers in neoadjuvant trials. Cancer Treat Res. 2009; 147:1-36.
    View in: PubMed
    Score: 0.083
  44. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 2008 Oct 01; 68(19):7966-74.
    View in: PubMed
    Score: 0.081
  45. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2007 Dec 01; 67(23):11272-83.
    View in: PubMed
    Score: 0.077
  46. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Oct 15; 104(8):1779-80; author reply 1780.
    View in: PubMed
    Score: 0.066
  47. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers (Basel). 2020 Mar 18; 12(3).
    View in: PubMed
    Score: 0.045
  48. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat. 2012 Apr; 132(2):575-88.
    View in: PubMed
    Score: 0.025
  49. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068.
    View in: PubMed
    Score: 0.021
  50. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 2009 Jun; 115(3):651-9.
    View in: PubMed
    Score: 0.021
  51. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res. 2007 Oct 15; 13(20):6032-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.